Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Conditions
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Contact: Principal Investigator (Richard DRACHTMAN)Columbia University Medical Center New York Presbyterian, New York, New York, United States
Contact: Principal Investigator (Nobuko Hijiya)Novartis Investigative Site, Brisbane, Queensland, Australia
Novartis Investigative Site, North Adelaide, South Australia, Australia
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Zhengzhou, Henan, China
Novartis Investigative Site, Tianjin, China
Novartis Investigative Site, Marseille, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Strasbourg, France
Novartis Investigative Site, Yokohama, Kanagawa, Japan
Novartis Investigative Site, Saitama, Japan
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Madrid, Spain
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals